抗菌药物靶标丙氨酸消旋酶及其抑制剂研究进展

抗生素的滥用和人口的大量流动使得病原菌耐药性增强并与其他病原体产生共感染等问题,严重威胁人类的生命安全,因此,研发新型抗菌药物成为人类亟待解决的问题。丙氨酸消旋酶是以磷酸吡哆醛为辅酶催化L-丙氨酸与D-丙氨酸旋光结构互换的一类异构酶,其消旋产物D-丙氨酸对细菌细胞壁的形成具有决定性作用,与细菌性疾病密切相关。抑制丙氨酸消旋酶的活性会影响细菌的生存,近年来成为设计抗菌药物的一个理想靶位,其抑制剂的开发已成为抗菌药物研发的热点。本文从丙氨酸消旋酶的来源、结构、功能、应用及抑制剂等方面进行系统阐述,并对丙氨酸消旋酶的研究提出新的策略,为进一步研究丙氨酸消旋酶与致病菌的关系及抗菌药物候选靶标的研究提供理论基础。     

以蛋白激酶B为靶点的新型抗结核药物高通量筛选模型的建立和应用

【目的】建立以结核分枝杆菌蛋白激酶B为靶点的高通量筛选模型,并运用此模型进行化合物的筛选。【方法】克隆和表达结核分枝杆菌蛋白激酶B,并以其为靶酶建立并优化PknB抑制剂高通量筛选模型,利用该模型对化合物样品进行筛选,并对筛选到的阳性化合物进行抗菌和抑酶活性评价。【结果】利用该模型筛选了化合物样品18 000个,得到具有抑酶活性的阳性化合物8个,其中3个化合物具有较好的对结核分枝杆菌、海分枝杆菌、耻垢分枝杆菌的抑菌活性。【结论】建立的以PknB为靶点的抗结核药物高通量筛选模型具有灵敏度高、稳定性强等优点,可成功用于化合物的高效筛选。筛选得到3个在抑酶水平和抗菌方面均具有良好活性的阳性化合物样品,值得进一步研究。     

新型抗结核分枝杆菌药物筛选模型的建立

为建立基于酶水平和细胞水平的新型抗结核分枝杆菌（Mycobacterium tuberculosis）药物的筛选模型,以M.tuberculosis H37Rv基因组DNA为模板,PCR特异性扩增异柠檬酸裂解酶（ICL）基因,构建表达载体,在E.coli BL21（DE3）中高效表达,使用N i2＋亲和层析柱纯化重组ICL,检测其活性。优化ICL酶反应条件,考察待筛选样品溶剂对酶活性的影响,建立ICL抑制剂酶水平筛选模型;考察与优化耻垢分枝杆菌（Mycobacterium smegma）在以乙酸盐为唯一碳源的培养基中的生长状况,建立基于M.sm egma的乙醛酸代谢途径抑制剂的细胞水平筛选模型;利用上述2种筛选模型对1 060种可能具有拮抗活性的微生物代谢样品进行初筛和复筛,两者筛选结果正相关性较好。     

以内含肽为靶点的结核分枝杆菌抑制剂的筛选

根据WHO资料,全世界每年有200万人死于各型结核病,它的致病菌是结核分枝杆菌。据2000年我国结核病流行病学抽样调查数据显示,全国有活动性肺结核病人500万,每年约有13万人死于结核病。艾滋病／结核病的双重感染,将加重我国结核病疫情。耐药是结核病控制需要重点关注的问题,全国有耐药病人55．5万。所以开发新的抗结核药物是迫切的,     

抗菌药物治疗疾病的新靶位——丙氨酸消旋酶

丙氨酸消旋酶是以磷酸吡哆醛为辅酶,催化L-丙氨酸与D-丙氨酸相互转化的一种酶,它广泛分布在低等生物,而不存在于人类等高等真核生物中.来自不同物种的丙氨酸消旋酶一级结构同源性较高,其大多功能单位为同源二聚体,拥有2个相同的活性中心,每个活性中心均是由来自不同亚基的2个保守残基共同组成.丙氨酸消旋酶催化生成的产物D-丙氨酸是合成细菌细胞壁肽聚糖的重要成分,也是调节细菌孢子萌芽的关键因子.因而丙氨酸消旋酶与由细菌引起的肺结核、炭疽热、中耳炎等疾病密切相关.近年来丙氨酸消旋酶已成为设计抗菌药物的又一理想靶位.本文从丙氨酸消旋酶的结构、功能、作用机理、抑制剂以及其与疾病的关系等方面进行了阐述.     

以蛋白激酶G为靶点的抗结核药物筛选模型

<正>结核分枝杆菌在被巨噬细胞吞噬、形成吞噬体后,可以通过阻止吞噬体的成熟及其与溶酶体的融合,而使其自身不被溶酶体酶降解,从而在巨噬细胞内长期存留下来。此时的细菌代谢活动降至最低,生长繁殖几乎停止,不易被抗菌药物杀灭,这种类似于休眠的长期存活状态被称为"持留"状态。当机体免疫力下降时,     

丙氨酸消旋酶C-端结构域重组体的构建及其功能初探

[目的]将嗜碱芽孢杆菌丙氨酸消旋酶OF4DadX的N-端结构域分别与多个不同种属的丙氨酸消旋酶C-端结构域重组,探究丙氨酸消旋酶C-端结构域功能.[方法]利用基因拼接构建丙氨酸消旋酶重组基因,通过镍亲和层析纯化酶蛋白,采用D-氨基酸氧化酶偶联法检测重组酶蛋白的酶学特性,借助分子筛和HPLC液相色谱分析其聚合状态及动力学...     

结核分枝杆菌DNA糖基化酶TagA的表达、纯化及晶体学研究

结核病的病原体结核分枝杆菌是最致命的传染病病原体之一,然而2019年新冠疫情对结核病防治工作造成了沉重打击,因此对结核分枝杆菌进行深入研究有着重要的意义。基因组学的研究表明,结核分枝杆菌来源Ⅰ型3-甲基腺嘌呤DNA糖基化酶TagA(Mtb TagA)可识别和切除受损烷基化碱基,以此维持基因组的正常复制、转录和翻译,但其结合底物的类型、催化机制以及结构基础尚不清楚。在大肠杆菌中异源表达Mtb TagA,通过镍介质亲和层析、离子交换层析以及凝胶过滤层析的方法获得高纯度的蛋白。动态光散射(DLS)试验发现Mtb Tag A蛋白以单体分布于溶液中,可与底物次黄嘌呤(Hx)和3-甲基腺嘌呤(3MA)结合,并改变其聚集状态。进一步结晶筛选优化出片状晶体,通过X光衍射获得分辨率为7?的衍射数据。该研究为进一步探究DNA糖基化酶蛋白的生化性质和结构性质提供了参考。     

以蛋白激酶G为靶点的抗结核药物筛选模型的建立和初步应用

结核分枝杆菌可以产生11种丝氨酸/苏氨酸蛋白激酶,其中蛋白激酶G(PknG)对于结核分枝杆菌在巨噬细胞内以"持留"状态长期存活有着重要作用。本研究以结核分枝杆菌基因组DNA为模板,在大肠杆菌中克隆表达了MTBPknG蛋白,并分离纯化得到PknG纯酶。本研究还采用三步级联反应方法测定了PknG酶活性,建立和优化了PknG抑制剂高通量筛选模型。利用此模型共筛选发酵液样品2120个,化合物样品2300个,筛选得到阳性化合物1个,阳性发酵液13个,阳性率0.32%。     

以苯丙氨酰-tRNA合成酶为靶点的新型抗结核药物高通量筛选模型的建立和应用

【目的】建立结核分枝杆菌PheRS抑制剂高通量模型,并运用此模型筛选化合物和发酵液样品。【方法】克隆和表达结核分枝杆菌PheRS蛋白并优化其酶活测定方法,在此基础上建立结核分枝杆菌PheRS抑制剂高通量筛选模型,并通过耻垢分枝杆菌作为检定菌对筛选到的样品进行抗菌活性测定及细胞毒性评价。【结果】运用此模型筛选了化合物样品11 600个,发酵液样品5 200个,筛选得到阳性化合物9个,阳性发酵液37个。而后通过耻垢分枝杆菌作为检定菌的抗菌活性测定及细胞毒性评价后,得到了6个发酵液阳性样品。【结论】建立的PheRS抑制剂模型可成功用于化合物和微生物发酵液的高效筛选,得到的6个发酵液阳性样品在酶水平和抗分枝杆菌方面均具有良好活性且毒性较低,值得进一步研究。     

Characterization of the alanine racemases from two mycobacteria

D-Alanine is a necessary precursor in the biosynthesis of the bacterial peptidoglycan. The naturally occurring L-alanine isomer is racemized to its D-form through the action of a class of enzymes called alanine racemases. These enzymes are ubiquitous among prokaryotes, and with very few exceptions are absent in eukaryotes, making them a logical target for the development of novel antibiotics. The alanine racemase gene from both Mycobacterium tuberculosis and M. avium was amplified by PCR and cloned in Escherichia coli. Overexpression of the proteins in the E. coli BL21 system, both as native and as His-tagged recombinant products, has been achieved. The proteins have been purified to electrophoretic homogeneity and analyzed biochemically. A D-alanine requiring double knock-out mutant of E. coli (alr, dadX) was constructed and the cloned genes were able to complement its deficiencies.     

Induced fit docking,free energy calculation and molecular dynamics studies on Mycobacterium tuberculosis alanine racemase inhibitor

Alar, a Pyridoxal 5′-phosphate (PLP)-dependent bacterial enzyme is responsible for the racemisation of L-alanine into D-alanine which is essential for the peptidoglycan biosynthesis in both Gram-positive and Gram-negative bacteria. In the present study, we performed induced fit docking, binding free energy calculation and molecular dynamics simulation to elucidate the Alar inhibition potential of 1,2,4-thiadiazolidine-3,5-dione-based inhibitor 1. The inhibitor binds to the hydrophobic groove of Alar and the binding was found to be stable throughout 20-ns MD simulation. Induced fit docking result showed that Lys42, Tyr46, Tyr175 and Tyr364 residues are primarily responsible for the stabilisation of inhibitor–protein complex. Further, high negative van der Waals binding free energy value of –38.88 kcal/mol, indicated it as the main driving force for the inhibitor binding. Based on the information obtained from this study, we designed few molecules as potent Alar inhibitor. In order to gain structural insight and to validate the stability of complex, we performed 20-ns MD simulation of the designed molecule D1. Results obtained from this study can be used for the design of M. tuberculosis Alar potent inhibitors lacking affinity for the co-factor PLP.     

恶臭假单胞菌丙氨酸消旋酶基因的克隆、序列分析及表达

从恶臭假单胞菌(Pseudomonas putida)200的基因组出发,用PCR方法克隆到两个独立作用的丙氨酸消旋酶基因,称之为dadX和alr。DadX编码357个氨基酸长的多肽,计算分子量为38.82kDa,alr编码409个氨基酸长的多肽,计算分子量为44.182kDa。序列分析显示,DadX的氨基酸序列与Pseudomonas putidaKT2440,铜绿假单胞菌(Pseudomonas aeruginosa),鼠伤寒沙门氏菌(Salmonella typhimurium)和大肠杆菌(Escherichia coli)的DadX比较,相似性分别为96.64%、71.99%、44.88%和47.37%。Alr的氨基酸序列与Pseudomonas putidaKT2440比较,同源性为94.38%,而与铜绿假单胞菌(P.aeruginosa)、鼠伤寒沙门氏菌(S.typhimurium)和大肠杆菌(E.coli)的Alr比较,同源性均较低,分别为22.89%、25.72%和26.44%。在P.putida200的DadX和Alr氨基酸序列中部发现有对于酶活性至关重要的保守区域,如磷酸吡哆醛(PLP)结合位点。DadX和alr在大肠杆菌中得到表达,DadX丙氨酸消旋酶只对丙氨酸有消旋作用,而Alr丙氨酸消旋酶可以作用于丙氨酸和丝氨酸两种底物,且对丝氨酸特异性更高。Alr的表达不依赖于外源启动子,说明在其结构基因上游存在启动子结构。     

结核分枝杆菌耐药性的分子生物学研究进展

结核病一直是世界性问题,我国其发病情况尤为严重,是亚洲的第二大结核病发病国家。结核病治疗方面常使用抗生素作为首选药物,随着抗菌药的滥用,结核杆菌对多种抗菌药产生耐药性,结核病耐药患者增多,治疗难度增加。因此,结核杆菌耐药分子机制的研究更加重要,新型抗结核药物研制更加迫切。结核分枝杆菌的基因突变是引起耐药的主要分子学依据,因此基于结核分枝杆菌耐药性相关基因的深入探索,对于预防结核病的传播及治疗皆具有深远影响。本文从分子生物学角度分析了近年来结核分枝杆菌耐药性产生的原因及相关研究进展。     

Recent updates on drug resistance in Mycobacterium tuberculosis

Tuberculosis (TB) along with acquired immune deficiency syndrome and malaria rank among the top three fatal infectious diseases which pose threat to global public health, especially in middle and low income countries. TB caused by Mycobacterium tuberculosis (Mtb) is an airborne infectious disease and one-third of the world's population gets infected with TB leading to nearly 1·6 million deaths annually. TB drugs are administered in different combinations of four first-line drugs (rifampicin, isoniazid, pyrazinamide and ethambutol) which form the core of treatment regimens in the initial treatment phase of 6–9 months. Several reasons account for the failure of TB therapy such as (i) late diagnosis, (ii) lack of timely and proper administration of effective drugs, (iii) lower availability of less toxic, inexpensive and effective drugs, (iv) long treatment duration, (v) nonadherence to drug regimen and (vi) evolution of drug-resistant TB strains. Drug-resistant TB poses a significant challenge to TB therapy and control programs. In the background of worldwide emergence of 558 000 new TB cases with resistance to rifampicin in the year 2017 and of them, 82% becoming multidrug-resistant TB (MDR-TB), it is essential to continuously update the knowledge on the mechanisms and molecular basis for evolution of Mtb drug resistance. This narrative and traditional review summarizes the progress on the anti-tubercular agents, their mode of action and drug resistance mechanisms in Mtb. The aim of this review is to provide recent updates on drug resistance mechanisms, newly developed/repurposed anti-TB agents in pipeline and international recommendations to manage MDR-TB. It is based on recent literature and WHO guidelines and aims to facilitate better understanding of drug resistance for effective TB therapy and clinical management.     

Structure and function of psychrophilic alanine racemase

We describe the structure and function of psychrophilic alanine racemases from Bacillus psychrosaccharolyticus and Pseudomonas fluorescens. These enzymes showed high catalytic activities even at 0°C and were extremely labile at temperatures over 35°C. The enzymes were also found to be less resistant to organic solvents than alanine racemases from thermophilic and mesophilic bacteria, both in vivo and in vitro. Both enzymes have a dimeric structure and contain 2 mol of pyridoxal 5′-phosphate (PLP) per mol as a coenzyme. The enzyme from B. psychrosaccharolyticus was found to have a markedly large K_m value (5.0 μM) for PLP in comparison with other reported alanine racemases, and was stable at temperatures up to 50°C in the presence of excess amounts of PLP. The dissociation of PLP from the P. fluorescens enzyme may trigger the unfolding of the secondary structure. The enzyme from B. psychrosaccharolyticus has a distinguishing hydrophilic region around residue no. 150 in its deduced amino acid sequence, whereas the corresponding regions of other Bacillus alanine racemases are hydrophobic. The position of this region in the three dimensional structure of this enzyme was predicted to be in a surface loop surrounding the active site. This hydrophilic region may interact with solvent, reduce the compactness of the active site, and destabilize the enzyme.     

High catalytic activity of alanine racemase from psychrophilic Bacillus psychrosaccharolyticus at high temperatures in the presence of pyridoxal 5'-phosphate

We examined the effect of the pyridoxal 5'-phosphate (PLP) cofactor on the activity and stability of the psychrophilic alanine racemase, having a high catalytic activity at low temperature, from Bacillus psychrosaccharolyticus at high temperatures. The decrease in the enzyme activity at incubation temperatures over 40 degrees C was consistent with the decrease in the amount of bound PLP. Unfolding of the enzyme at temperatures above 40 degrees C was suppressed in the presence of PLP. In the presence of 0.125 mM PLP, the specific activity of the psychrophilic enzyme was higher than that of a thermophilic alanine racemase, having a high catalytic activity at high temperature, from Bacillus stearothermophilus even at 60 degrees C.     

Molecular characterization of alanine racemase from Bifidobacterium bifidum

Bifidobacterium bifidum is a useful probiotic agent exhibiting health-promoting properties, and its peptidoglycans have the potential for applications in the fields of food science and medicine. We investigated the bifidobacterial alanine racemase, which is essential in the synthesis of -alanine as an essential component of the peptidoglycans. Alanine racemase was purified to homogeneity from a crude extract of B. bifidum NBRC 14252. It consisted of two identical subunits with a molecular mass of 50 kDa. The enzyme required pyridoxal 5′-phosphate (PLP) as a coenzyme. The activity was lost in the presence of a thiol-modifying agent. The enzyme almost exclusively catalyzed the alanine racemization; other amino acids tested, except for serine, were inactive as substrates. The kinetic parameters of the enzyme suggested that the B. bifidum alanine racemase possesses comparatively low affinities for both the coenzyme (9.1 μM for PLP) and substrates (44.3 mM for -alanine; 74.3 mM for -alanine). The alr gene encoding the alanine racemase was cloned and sequenced. The alr gene complemented the -alanine auxotrophy of Escherichia coli MB2795, and an abundant amount of the enzyme was produced in cells of the E. coli MB2795 clone. The enzymologic and kinetic properties of the purified recombinant enzyme were almost the same as those of the alanine racemase from B. bifidum NBRC 14252.